Jasper leverages engineered biologics and cell-based approaches to address complications in hematologic conditions and improve transplant outcomes. The company demonstrates strategic positioning in the rare disease and regenerative medicine space, with a focus on translating immunobiology advances into clinical solutions. Recently appointed CEO Jeet Mahal is leading the company through its next phase of clinical growth.
Cyborg Score Rationale
While Jasper has promising early-stage clinical data with positive outcomes in CSU and CIndU studies, the company faces significant volatility and recent analyst downgrades. The clinical-stage status means no revenue, substantial burn rate, and regulatory execution risk, though analyst consensus remains "Moderate Buy" with potential for significant upside.
Top Insights
Lead asset briquilimab has demonstrated positive efficacy and safety in early clinical studies for chronic urticaria, with ongoing Phase trials in asthma
Recent analyst consensus shows "Moderate Buy" rating across 12-18 research firms covering the stock
Stock volatility is extreme (52-week range $1.39-$22.52), with significant analyst price target dispersion from $4 to $86 reflecting high execution risk
Institutional ownership at 72.51% suggests strong institutional backing, though recent analyst downgrades by RBC Capital (November 2025) indicate execution concerns
Named Competitors
Omalizumab — Marketed monoclonal antibody for chronic urticaria (IgE pathway)
Dupilumab — Marketed biologic for various allergic and inflammatory conditions
Other CD117 targeting programs — Early-stage programs targeting KIT/CD117 pathway in mast cell and stem cell indications
Recent Developments
(March 2026) Receives "Moderate Buy" consensus rating from 12 research firms
(November 2025) RBC Capital initiates coverage with $4 price target amid clinical trial concerns
(September 2025) Positive preliminary data from ETESIAN study in asthma reported
Open the full interactive Jasper Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.